It is more common after certain types of gastric or esophageal surgery
Abstract Background and Objectives Cagrilintide is a long-acting amylin agonist under development as monotherapy for weight management and as a fixed-dose combination with the glucagon-like peptide-1 receptor agonist semaglutide (CagriSema) for weight management and treatment of type 2 diabetes
WeightWatchers: companion programme for GLP-1 users In the UK, WeightWatchers GLP-1 programme is a companion service, not a prescriber
As of 2024, retatrutide has not received MHRA or EMA marketing authorisation and is not listed in the BNF
While B12 supports metabolism, proper nutrition is still the cornerstone of sustainable weight loss
Se determin que el uso de agonistas de GLP-1 se asoci con un mayor riesgo de pancreatitis (HR 9,09 [IC 95 %, 1,25-66]), obstruccin intestinal (HR 4,22 [IC 95 %, 1,02-17,4]) y gastroparesia (HR, 3,67 [IC 95%, 1,15-11,9]) pero no enfermedad biliar (HR 1,50 [IC del 95%, 0,89-2,53]) en comparacin con bupropin-naltrexona
